Recent Updates
Recently added Catalysts

Mosunetuzumab

Phase 3

Non-Hodgkin Lymphoma | Small molecule | Oncology |Roche Holding AG|Last Updated: Aug 31, 2026

Target and mechanism

Molecular targetMS4A1, CD3E, CD3G, CD3D
Target classBinding Agent
ModalitySmall molecule

Also known as SC Mosunetuzumab, Mosunetuzumab (IV), Mosunetuzumab (Cohorts A-C)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials3
Total Enrollment649

FDA Designations

No designations recorded

Clinical trial landscape

Mosunetuzumab · 12 trials · 10 indications

Phase 3 2Phase 2 2Phase 1 8
NCT05171647A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaNon-Hodgkin Lymphoma
ACTIVE NOT_RECRUITING208 Analytics
NCT04712097A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaRelapsed or Refractory Follicular Lymphoma
ACTIVE NOT_RECRUITING478 Analytics
PHASE3ACTIVE NOT_RECRUITING
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkin LymphomaUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Relapsed or Refractory Follicular LymphomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
Up to approximately 23.8 months

ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.

Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
Up to 32 months

PFS was defined as the time from randomization to first occurrence of disease progression (PD) or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.

Progression Free Survival (PFS) according to 2014 Lugano Response Criteria
From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years)
Proportion of participants who have achieved remission by Week 76
Up to Week 76

Drug-Free Remission is defined as achieving both of the following: Absence of disease activity maintained for 6 months after completion of mosunetuzumab treatment, and; not receiving any SLE-directed therapy (except for antimalarials) during the 6 months. Doses of prednisone (or equivalent) ≤5 mg/day to treat secondary adrenal insufficiency are permitted.

Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)
From the first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first, as determined by the investigator according to Lugano Criteria 2014 (minimum 2 years)
Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)
Cycles 4, 8, 12 and 17 (cycle length=21 days)
Incidence of dose limiting toxicities (DLTs) (phase Ib)
From the first dose of mosunetuzumab to the end of cycle 2 (1 cycle = 21 days)

Using a modified 3+3 design in previously untreated c-Myc rearranged aggressive B cell lymphomas during the safety run-in period (cycle 1-2). Incidence of DLTs will be tabulated by dose level. All DLTs will be coded by system organ class, MedDRA preferred term, and severity grade using Common Terminology Criteria for Adverse Events (CTCAE )(version \[v\] 5.0). Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome (CRS/ICANS) toxicities will be reporting using with the American Society for Transplantation and Cellular Therapy (ASTCT) grading system. Safe dose of mosunetuzumab (or dose adjusted \[DA\] etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone \[EOPCH\]) will be specified.

Proportion of patients with complete response by positron emission tomography-computed tomography (PET-CT) (phase II)
Up to 5 years

Will be reported with exact 95% confidence interval.

Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation]
Until 90 days after the final dose of study treatment
Percentage of participants with adverse events [all cohorts]
Until 90 days after the final dose of study treatment
Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]
Up to 2 years after start of primary study treatment
Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]
Until 90 days after the final dose of study treatment
Rate of Dose-Limiting Toxicities (DLTs)
Up to approximately 12 months (Arms A and B) or 24 months (Arm C)
Objective Response Rate (ORR) During Dose Expansion Phase
Up to 8-12 weeks after the last dose of study drug
Percentage of participants with adverse events (AEs)
For a minimum of 12 months after mosunetuzumab dose
Dose-Limiting Toxicities (DLTs)
Cycle 2 Days 1-28 (cycle length = 28 days)
Percentage of Participants with Adverse Events
From baseline to 90 days after the last dose of study drug
Cumulative Area under the Curve over Cycles 1-3 (AUC1-3) of Mosunetuzumab
Day 1 - Day 78
Serum Trough Concentration at Steady State Approximated by Cycle 4 (Ctrough, c4) of Mosunetuzumab
Day 106
Overall Response Rate (ORR) as Determined by the Independent Review Committee (IRC)
Up to the end of Cycle 12 (cycle length = 28 days)
Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A)
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B)
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C)
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)
6-8 weeks after either C6D1 or last dose of study treatment

The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.

Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin
Cycle 1 to Cycle 2 (cycle length = 21 days)
Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin
Cycle 1 to Cycle 2 (cycle length = 21 days)
Percentage of Participants with Adverse Events (AE)
Baseline through approximately 90 days after last study treatment
Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL
Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)

Secondary Endpoints

ORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population
Up to 32 months
ORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population
Up to approximately 58 months
Duration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
Up to 32 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
M+P (Arm A)EXPERIMENTALParticipants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
R-GemOx (Arm B)ACTIVE_COMPARATORParticipants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
M + Len (Arm A)EXPERIMENTALParticipants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
R + Len (Arm B)EXPERIMENTALParticipants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
M + Len (US Extension Arm C)EXPERIMENTALParticipants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
MosunetuzumabEXPERIMENTALParticipants will receive mosunetuzumab by subcutaneous (SC) injection.
Cohort AEXPERIMENTALParticipants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.
Cohort BEXPERIMENTALElderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Cohort CEXPERIMENTALParticipants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Cohort DEXPERIMENTALParticipants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Cohort EEXPERIMENTALParticipants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Treatment (Mosunetuzumab and EPOCH)EXPERIMENTALPatients receive mosunetuzumab IV, over 2-4 hours, on day 1, 8 and 15 of cycle 1 and day 1 of subsequent cycles. Patients receive etoposide IV, doxorubicin IV, and vincristine IV on days 1-4, cyclophosphamide IV, over 2 hours, on day 5 and prednisone PO BID on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles. Patients undergo bone marrow aspiration and biopsy, tumor biopsy and may undergo echocardiography or MUGA at screening and PET scan, CT scan or MRI and blood sample collection throughout the study.
Arm 1EXPERIMENTALParticipants will receive subcutaneous (SC) mosunetuzumab + CC-220 (dose escalation only) or SC mosunetuzumab + CC-99282.
Arm 2EXPERIMENTALParticipants will receive intravenous (IV) glofitamab + CC-99282.
Arm AEXPERIMENTALParticipants with R/R CLL/SLL after two prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab subcutaneous (SC) monotherapy
Arm BEXPERIMENTALParticipants with R/R CLL/SLL after two or more prior lines of therapy, who are currently progressing on BTKi therapy, and who require salvage therapy as assessed by their treating physician will receive mosunetuzumab SC with BTKi overlap therapy for up to the first three cycles of mosunetuzumab SC
Arm C (non-US participants only)EXPERIMENTALParticipants with R/R CLL/SLL after two or more prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab SC with venetoclax during dose escalation phase. Participants with R/R CLL/SLL after at least one prior line of therapy must have prior exposure to BTKi and/or venetoclax and \>12 months since last venetoclax exposure will receive mosunetuzumab SC with venetoclax during the dose expansion phase. During the dose expansion phase, a control cohort receiving the standard-of-care regimen of rituximab plus venetoclax has been added (this arm is open only to participants outside of the US).
Non-fractionated/Dose-findingEXPERIMENTALParticipants will receive a single dose of mosunetuzumab.
Fractionated/Dose-escalationEXPERIMENTALParticipants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized)EXPERIMENTALParticipants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized)EXPERIMENTALParticipants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will receive maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.
Arm A: IV Mosunetuzumab + Len (Randomized)EXPERIMENTALParticipants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
Arm B: SC Mosunetuzumab + Len (Randomized)EXPERIMENTALParticipants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
Consolidation Therapy (Cohort A)EXPERIMENTALParticipants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
Elderly/Unfit Previously Untreated Monotherapy (Cohort B)EXPERIMENTALElderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)EXPERIMENTALElderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
Phase Ib: Mosunetuzumab (M)-CHOP Dose FindingEXPERIMENTALParticipants will receive M-CHOP up to the phase II recommended dose (RP2D).
Phase Ib: M-CHP-Pola Dose-FindingEXPERIMENTALParticipants will receive M-CHP-Pola up to the RP2D.
Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety CohortEXPERIMENTALParticipants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
Phase II: M-CHP-Pola 1L DLBCLEXPERIMENTALParticipants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
Phase II: Rituxumab (R)-CHP-Pola 1L DLBCLACTIVE_COMPARATORParticipants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
Phase II: M-CHOP 1L DLBCLEXPERIMENTALParticipants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage. NOTE: No participants were enrolled to this arm.
Dose FindingEXPERIMENTALParticipants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FLEXPERIMENTALParticipants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.
Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCLEXPERIMENTAL2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.
Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCLEXPERIMENTALParticipants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.
Mosunetuzumab SC + Polatuzumab Vedotin 2L+R/R DLBCLEXPERIMENTAL2L+ participants with R/R DLBCL will receive SC mosunetuzumab and polatuzumab vedotin.

Interventions

NameTypeDescription
MosunetuzumabDRUGParticipants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Polatuzumab vedotinDRUGParticipants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
TocilizumabDRUGParticipants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
RituximabDRUGParticipants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
GemcitabineDRUGParticipants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
OxaliplatinDRUGParticipants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
LenalidomideDRUGParticipants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
TociluzumabDRUGTocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
Mosunetuzumab (Cohorts A-C)DRUGParticipants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
Mosunetuzumab (Cohorts D-E)DRUGParticipants will receive SC mosunetuzumab for up to 34 cycles
BiopsyPROCEDUREUndergo tumor biopsy
Biospecimen CollectionPROCEDUREUndergo blood sample collection
Bone Marrow Aspiration and BiopsyPROCEDUREUndergo bone marrow aspiration and biopsy
Computed TomographyPROCEDUREUndergo CT scan
CyclophosphamideDRUGGiven IV
DoxorubicinDRUGGiven IV
EchocardiographyPROCEDUREUndergo echocardiography
EtoposideDRUGGiven IV
Magnetic Resonance ImagingPROCEDUREUndergo MRI
Multigated Acquisition ScanPROCEDUREUndergo MUGA
Positron Emission TomographyPROCEDUREUndergo PET scan
PrednisoneDRUGGiven PO
VincristineDRUGGiven IV
SC MosunetuzumabDRUGParticipants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
IV GlofitamabDRUGParticipants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
IberdomideDRUGArm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
GolcadomideDRUGArm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
ObinutuzumabDRUGParticipants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
VenetoclaxDRUGParticipants will receive daily oral venetoclax.
Mosunetuzumab (IV)DRUGParticipants will receive IV mosunetuzumab as defined by the study protocol
Mosunetuzumab (SC)DRUGParticipants will receive SC mosunetuzumab as defined by the study protocol
Mosunetuzumab Intravenous (IV)DRUGParticipants in cohorts A and B will receive IV mosunetuzumab.
Mosunetuzumab Subcutaneous (SC)DRUGParticipants in Cohort C will receive SC mosunetuzumab.
RituxumabDRUGParticipants will receive rituxumab via IV.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites51

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise ...

Countries:United StatesArgentinaBrazilCanadaChinaIsraelJapanMexicoNew ZealandPeruSouth KoreaThailandTurkey (Türkiye)AustraliaFranceGermanyItalyPolandRussiaSpainTaiwanUnited KingdomColombiaSouth AfricaMoldovaAustriaBelgium
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWAug 31, 2026NCT05207670lastUpdatePostDate: changed
LOWAug 31, 2026NCT05207670lastUpdatePostDate: changed
LOWAug 21, 2026NCT07598396lastUpdatePostDate: changed
LOWAug 21, 2026NCT07598396lastUpdatePostDate: changed
LOWAug 17, 2026NCT05169515primaryCompletionDate: changed
LOWAug 17, 2026NCT05169515primaryCompletionDate: changed
MEDIUMAug 11, 2026NCT05169515Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMAug 11, 2026NCT05169515Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMAug 11, 2026NCT05169515Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWAug 5, 2026NCT05091424lastUpdatePostDate: changed
LOWAug 5, 2026NCT05171647lastUpdatePostDate: changed
LOWAug 1, 2026NCT07598396lastUpdatePostDate: changed
LOWAug 1, 2026NCT07598396lastUpdatePostDate: changed
LOWAug 1, 2026NCT07598396lastUpdatePostDate: changed

Frequently asked questions about Mosunetuzumab

What is Mosunetuzumab used for?

Mosunetuzumab is an investigational antibody being studied for Diffuse Large B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Relapsed or Refractory Follicular Lymphoma, Follicular Lymphoma, and Lupus. It is in Phase 1 clinical development for these conditions.

What does Mosunetuzumab target?

Mosunetuzumab is a monoclonal antibody (mab) that targets CD20 on B-cells. It is designed to engage T-cells to eliminate malignant B-cells in B-cell malignancies and modulate B-cells in autoimmune conditions like Lupus.

Who makes Mosunetuzumab?

Mosunetuzumab is developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The company is conducting multiple Phase 1 trials of the drug across oncology and autoimmune indications.

What phase is Mosunetuzumab in?

Mosunetuzumab is in Phase 1 clinical development. It is investigational and not yet approved by regulatory authorities. All four listed trials are Phase 1 studies, with three active or recruiting and one completed.

What clinical trials is Mosunetuzumab in?

Mosunetuzumab is being studied in four Phase 1 trials: NCT03677154 in Diffuse Large B-cell Lymphoma, NCT04246086 in Follicular Lymphoma, NCT05155345 in Systemic Lupus Erythematosus, and NCT06249191 in Diffuse Large B-cell Lymphoma and High Grade B-Cell Lymphoma.

Is Mosunetuzumab the same as SC Mosunetuzumab?

Yes, SC Mosunetuzumab refers to the subcutaneous formulation of Mosunetuzumab. The drug is also known as Mosunetuzumab (IV) for the intravenous formulation and Mosunetuzumab (Cohorts A-C) in certain trial cohorts.